OS Therapies’ (OSTX) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of OS Therapies (NYSEAMERICAN:OSTX) in a research note released on Monday morning,Benzinga reports. The firm currently has a $20.00 price target on the stock.

Separately, Zacks Research upgraded shares of OS Therapies from a “strong sell” rating to a “hold” rating in a report on Tuesday, November 11th. Three investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, OS Therapies has a consensus rating of “Moderate Buy” and an average target price of $17.33.

OS Therapies Stock Down 4.6%

NYSEAMERICAN:OSTX opened at $1.65 on Monday. The firm has a 50-day moving average price of $1.96 and a 200 day moving average price of $1.90. OS Therapies has a 12-month low of $1.12 and a 12-month high of $7.00. The firm has a market capitalization of $58.10 million, a PE ratio of -2.01 and a beta of -4.10.

OS Therapies (NYSEAMERICAN:OSTX) last released its quarterly earnings results on Friday, November 14th. The company reported ($0.21) earnings per share (EPS) for the quarter. On average, research analysts expect that OS Therapies will post -0.64 EPS for the current year.

Institutional Trading of OS Therapies

A number of institutional investors and hedge funds have recently modified their holdings of the business. Susquehanna International Group LLP bought a new position in shares of OS Therapies during the 3rd quarter worth $29,000. Ground Swell Capital LLC purchased a new position in OS Therapies in the 3rd quarter valued at approximately $40,000. Mercer Global Advisors Inc. ADV purchased a new position in OS Therapies in the 3rd quarter valued at approximately $40,000. Bridgeway Capital Management LLC bought a new stake in OS Therapies during the 2nd quarter valued at $47,000. Finally, XTX Topco Ltd purchased a new stake in shares of OS Therapies during the second quarter worth $63,000.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.